Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings
Implementation of an Evidence Based PTSD Treatment in Public Sector Settings
Status: Enrolling
Updated:  9/2/2015
The Nathan S. Kline Institute for Psychiatric Research (NKI)
mi
from
Orangeburg, NY
Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings
Implementation of an Evidence Based PTSD Treatment in Public Sector Settings
Status: Enrolling
Updated: 9/2/2015
The Nathan S. Kline Institute for Psychiatric Research (NKI)
mi
from
Orangeburg, NY
Click here to add this to my saved trials
Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings
Implementation of an Evidence Based PTSD Treatment in Public Sector Settings
Status: Enrolling
Updated:  9/2/2015
London Health Sciences Centre
mi
from
London,
Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings
Implementation of an Evidence Based PTSD Treatment in Public Sector Settings
Status: Enrolling
Updated: 9/2/2015
London Health Sciences Centre
mi
from
London,
Click here to add this to my saved trials
Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD
Pilot Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD
Status: Enrolling
Updated:  9/3/2015
VA Palo Alto Health Care System
mi
from
Menlo Park, CA
Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD
Pilot Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD
Status: Enrolling
Updated: 9/3/2015
VA Palo Alto Health Care System
mi
from
Menlo Park, CA
Click here to add this to my saved trials
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated:  9/4/2015
Individual homes of subjects
mi
from
Not Predetermined, CT
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated: 9/4/2015
Individual homes of subjects
mi
from
Not Predetermined, CT
Click here to add this to my saved trials
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated:  9/4/2015
Juvenile Bipolar Research Foundation
mi
from
Maplewood, NJ
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated: 9/4/2015
Juvenile Bipolar Research Foundation
mi
from
Maplewood, NJ
Click here to add this to my saved trials
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated:  9/4/2015
Individual homes of subjects
mi
from
Not Predetermined, NJ
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated: 9/4/2015
Individual homes of subjects
mi
from
Not Predetermined, NJ
Click here to add this to my saved trials
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated:  9/4/2015
Individual homes of subjects
mi
from
Not Predetermined, NY
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
Status: Enrolling
Updated: 9/4/2015
Individual homes of subjects
mi
from
Not Predetermined, NY
Click here to add this to my saved trials
Ketamine/Placebo Family History Positive Study
GABA Mechanisms Underlying the Vulnerability for Alcohol Dependence
Status: Enrolling
Updated:  9/8/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Ketamine/Placebo Family History Positive Study
GABA Mechanisms Underlying the Vulnerability for Alcohol Dependence
Status: Enrolling
Updated: 9/8/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Status: Enrolling
Updated:  9/8/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Status: Enrolling
Updated: 9/8/2015
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
Internet-Based Interventions for Bipolar Disorder
2/2-A Randomized Trial of Internet-Based Interventions for Bipolar Disorder
Status: Enrolling
Updated:  9/8/2015
VA Palo Alto Healthcare System
mi
from
Palo Alto, CA
Internet-Based Interventions for Bipolar Disorder
2/2-A Randomized Trial of Internet-Based Interventions for Bipolar Disorder
Status: Enrolling
Updated: 9/8/2015
VA Palo Alto Healthcare System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Distress Tolerance and Buprenorphine
Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients
Status: Enrolling
Updated:  9/9/2015
Butler Hospital
mi
from
Providence, RI
Distress Tolerance and Buprenorphine
Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients
Status: Enrolling
Updated: 9/9/2015
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Birmingham, AL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Phoenix, AZ
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Encino, CA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Encino, CA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Escondido, CA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Escondido, CA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Fresno, CA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Long Beach, CA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Newport Beach, CA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Orange, CA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Norwalk, CT
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Washington,
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Atlantis, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Deerfield Beach, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Delray Beach, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Delray Beach, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Lake Worth, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Oakland Park, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Oakland Park, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Orlando, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Port Charlotte, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Sarasota, FL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Columbus, GA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Columbus, GA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Savannah, GA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Springfield, IL
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Easton, MD
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Easton, MD
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Winchester, MA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Winchester, MA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
St. Paul, MN
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
St. Paul, MN
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Rochester, NY
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Charlotte, NC
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Durham, NC
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Wilmington, NC
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Winston Salem, NC
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Winston Salem, NC
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Oklahoma City, OK
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Portland, OR
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Abington, PA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Abington, PA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Jenkintown, PA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Jenkintown, PA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Norristown, PA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Norristown, PA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Pittsburgh, PA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Port Royal, SC
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Port Royal, SC
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
DeSoto, TX
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
DeSoto, TX
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Bellevue, WA
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  9/9/2015
TransitionTIL Investigational Site
mi
from
Toronto,
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 9/9/2015
TransitionTIL Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials